Cellectar Biosciences (CLRB): Balans kapitallashuviga qarzlar

Cellectar Biosciences Inc (CLRB) tovar belgisi

Cellectar Biosciences (CLRB) uchun o'sish asosi monopol narx belgilash imkoniyati va past ishlab chiqarish xarajatlariga ega bo'lgan radiofarmatsevtika vositalariga asoslangan. Kompaniyaning qarzning kitob kapitalizatsiyasiga nisbati ushbu tendentsiyani tasdiqlaydi, bunda parametr qiymati 0.05 ga tengdir. Biznesning barqarorligi izotoplarni o'smalarga yetkazib berishning noyob usuliga asoslangan, operatsion faoliyat esa xavfli chiqindilarni utilizatsiya qilish bo'yicha qat'iy davlat nazoratiga tayanadi.

Cellectar Corp (CLRB): Qarzning sof aktivlarga nisbati 04.07.2022dan 27.10.2026gacha

Cellectar Biosciences Inc (CLRB) boʻyicha maʼlumotlarning jamlanma tahliliy kesimlari

- narx va narxlar bo'yicha konsensus prognoz:
Narx grafigi Cellectar Biosciences|CLRB - Investitsiya uylarining umumiy prognozi
- bozor kapitallashuvi bo'yicha ma'lumotlar:
Bozor kapitallashuvi Cellectar Corp|CLRB - Korxonaning umumiy qiymati
- balans kapitallashuvi bo'yicha ma'lumotlar:
Bitta aksiya uchun sof aktivlar Cellectar Biosciences|CLRB - Kompaniyaning buxgalteriya qiymati|Bozor kapitallashuvining balans qiymatiga nisbati cellectar.com|CLRB - Kompaniyaning umumiy aktivlari
- qarz va likvidlik bo'yicha ma'lumotlar:
Qarzning xususiy kapitalga nisbati Cellectar Biosciences|CLRB - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzning o'z kapitaliga nisbati Cellectar|CLRB - Jamlangan qarz majburiyatlari|Qarzning balans kapitallashuviga nisbati Cellectar Corp
Kompaniyaning jamlanma tahliliyoti:Cellectar Biosciences - CLRB
Cellectar Corp original mahsuloti

Cellectar Biosciences (CLRB) muvaffaqiyati Waldenström makroglobulinemiyasidagi o'smalarga radioizotoplarni yetkazib berish aniqligiga bog'liq. Ushbu koeffitsient qarz mablag'lari hajmini kapitalning balans qiymatiga solishtirib, moliyaviy leveraj darajasini belgilaydi. Ushbu ko'rsatkichning oshishi likvidlilik xatarlarini yoki tadqiqot va ishlanmalar uchun strategik moliyalashtirishni anglatishi mumkin. Investorlar ushbu muvozanatni biznes barqarorligining o'lchovi sifatida baholaydilar. Ushbu nisbatlarning dinamikasi kompaniyaning qarzning kapitalizatsiyaga nisbati profilida aniq ko'rsatilgan.

Cellectar Biosciences kimlar bilan raqobatlashadi

INCY - Qarzning balans kapitallashuviga nisbati|Qarzning balans qiymatiga nisbati hutch-med.com HCM|NUVB (Nuvation Bio) - Balans kapitallashuviga qarzlar|DAWN: Balans qiymatiga qarzlar|Qarzning balans kapitallashuviga nisbati Monopar Pharma MNPR|Inhibrx Corp (INBX) - Qarzning sof aktivlarga nisbati|IMAB (I-Mab Biopharma Co., Ltd.) - Balans kapitallashuviga qarzlar|Balans kapitallashuviga qarzlar FENC|Qarzning balans kapitallashuviga nisbati Heron Therapeutics (HRTX)|Qarzning balans kapitallashuviga nisbati Nuvectis Pharma Inc. NVCT|Qarzning balans qiymatiga nisbati coherus.com|Corbus Pharmaceuticals, Inc. - Qarzning sof aktivlarga nisbati|CRDF (Cardiff Oncology Corp) - Qarzning balans kapitallashuviga nisbati|BYSI: Balans qiymatiga qarzlar|Qarzning balans kapitallashuviga nisbati bioatla.com|Lixte Biotechnology Holdings Inc. (LIXT) - Qarzning balans qiymatiga nisbati|Balans kapitallashuviga qarzlar CTXR|Qarzning balans qiymatiga nisbati BLRX|Can-Fite BioPharma - Qarzning balans kapitallashuviga nisbati|Balans qiymatiga qarzlar APRE (aprea.com)|Qarzning balans kapitallashuviga nisbati Kazia Therapeutics Limited KZIA|Silexion Therapeutics Corp. - Qarzning balans kapitallashuviga nisbati|NCNA (NuCana Corp) - Qarzning balans kapitallashuviga nisbati|CMRX - Balans qiymatiga qarzlar|Balans kapitallashuviga qarzlar CYCC (Cyclacel Pharmaceuticals)|Qarzning sof aktivlarga nisbati G1 Therapeutics|Qarzning balans qiymatiga nisbati KRON (Kronos Bio)|Balans qiymatiga qarzlar Kintara Therapeutics Inc (KTRA)|Oncternal (ONCT) - Qarzning balans qiymatiga nisbati|Qarzning sof aktivlarga nisbati Portage Biotech Corp PRTG